Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics, retaining the price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Voyager Therapeutics’ strategic positioning in the genetic medicines sector. The FDA’s recent draft guidances, which support innovative trial designs and the use of real-world evidence, align well with Voyager’s TRACER capsid engineering platform and its focus on neurodegenerative diseases. These regulatory endorsements enhance Voyager’s ability to leverage shared data across its programs, particularly in rare CNS disorders where traditional trials are difficult.
Furthermore, the FDA’s recognition of platform technologies is expected to accelerate the development of Voyager’s portfolio, as it allows for the use of adaptive and externally controlled trial designs. This flexibility could lead to more efficient and cost-effective drug development, providing a significant advantage in delivering therapies for rare neurodegenerative diseases. As a result, Trucchio reiterates a Buy rating with a $30 price target on VYGR, reflecting confidence in the company’s potential for growth and innovation in the genetic medicines landscape.
In another report released on October 2, Oppenheimer also maintained a Buy rating on the stock with a $18.00 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VYGR in relation to earlier this year.